242 related articles for article (PubMed ID: 27974704)
21. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
22. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
[TBL] [Abstract][Full Text] [Related]
23. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
25. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
26. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
27. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
28. ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.
Muniyan S; Chen SJ; Lin FF; Wang Z; Mehta PP; Batra SK; Lin MF
Cell Signal; 2015 Nov; 27(11):2261-71. PubMed ID: 26257301
[TBL] [Abstract][Full Text] [Related]
29. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
[TBL] [Abstract][Full Text] [Related]
30. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
31. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY
Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872
[TBL] [Abstract][Full Text] [Related]
32. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase.
Gesmundo I; Di Blasio L; Banfi D; Villanova T; Fanciulli A; Favaro E; Gamba G; Musuraca C; Rapa I; Volante M; Munegato S; Papotti M; Gontero P; Primo L; Ghigo E; Granata R
Cancer Lett; 2019 May; 449():252-262. PubMed ID: 30790678
[TBL] [Abstract][Full Text] [Related]
33. Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells.
Muniyan S; Chou YW; Ingersoll MA; Devine A; Morris M; Odero-Marah VA; Khan SA; Chaney WG; Bu XR; Lin MF
Cancer Lett; 2014 Oct; 353(1):59-67. PubMed ID: 25050738
[TBL] [Abstract][Full Text] [Related]
34. Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.
Liu S; Qi Y; Ge Y; Duplessis T; Rowan BG; Ip C; Cheng H; Rennie PS; Horikawa I; Lustig AJ; Yu Q; Zhang H; Dong Y
Mol Cancer Ther; 2010 Jul; 9(7):2016-25. PubMed ID: 20571066
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
36. MED12 overexpression is a frequent event in castration-resistant prostate cancer.
Adler D; Offermann A; Braun M; Menon R; Syring I; Nowak M; Halbach R; Vogel W; Ruiz C; Zellweger T; Rentsch CA; Svensson M; Andren O; Bubendorf L; Biskup S; Duensing S; Kirfel J; Perner S
Endocr Relat Cancer; 2014 Aug; 21(4):663-675. PubMed ID: 24938407
[TBL] [Abstract][Full Text] [Related]
37. Role of protein S in castration-resistant prostate cancer-like cells.
Ning P; Zhong JG; Jiang F; Zhang Y; Zhao J; Tian F; Li W
Endocr Relat Cancer; 2016 Aug; 23(8):595-607. PubMed ID: 27342144
[TBL] [Abstract][Full Text] [Related]
38. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Khanna A; Rane JK; Kivinummi KK; Urbanucci A; Helenius MA; Tolonen TT; Saramäki OR; Latonen L; Manni V; Pimanda JE; Maitland NJ; Westermarck J; Visakorpi T
Oncotarget; 2015 Aug; 6(23):19661-70. PubMed ID: 25965834
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
Lu PW; Li L; Wang F; Gu YT
J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Prostate Cancer DU-145 Cells Proliferation by
Li X; Tang Y; Yu F; Sun Y; Huang F; Chen Y; Yang Z; Ding G
Mar Drugs; 2018 Sep; 16(9):. PubMed ID: 30208576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]